GENERIC NAME/

TRADE NAME

CLASSIFICATION

INDICATION

MECHANISM
OF ACTION

ADVERSE
REACTION

DRUG
INTERACTION

ROUTE/
FREQUENCY/
DOSAGE

NURSING INTERVERNTIONS
GENERIC
NAME:
CEFTRIAXONE

BRAND
NAME: (KEPT
RIX)

Therapeutic Class:
Antibiotic

Pharmacologic
Class: Third-
Generation
Cephalosporin
Treatment of
infections of the
lower respiratory
tract, acute
bacterial otitis
media, skin & skin
structure
infection, UTI
Inhibits cell-wall
synthesis, promoting
osmotic instability,
usually bactericidal
Central Nervous
System- Dizziness,
Headache

Gastrointestinal-
Diarrhea, nausea
and vomiting.

Blood- High
concentration of
eosinophils,
platelet counts in
the blood,
decrease in white
blood cells, low
prothrombin
levels, bleeding


Drug-drug:
-CNS
DEPRESSANTS-
may cause
additive effect.
Monitor closely
for excessive
sedation or other
adverse effects.
-Theophylline-
May decrease
cetirizine
clearance.
Monitor patient
closely.



IV,
1g,
q 12
Assess patients
previous sensitivity reaction to
penicillin or other
cephalosporin.
Assess patient for signs
and symptoms of infection
before and during the
treatment
Obtain C&S before
beginning drug therapy to
identify if correct treatment
has been initiated.
Assess for allergic
reaction.
Monitor hematologic,
electrolytes, renal and hepatic
function.
Assess for possible super
infection: itching fever, malaise,
redness, diarrhea


GENERIC NAME/
TRADE NAME

CLASSIFICATION

INDICATION

MECHANISM
OF ACTION

ADVERSE
REACTION

DRUG
INTERACTION

ROUTE/
FREQUENCY/
DOSAGE

NURSING INTERVERNTIONS
G ENERIC
NAME:
RANITIDINE

BRAND
NAME:
ULCEPAC

Therapeutic Class:
Anti-ulcer agents

Pharmacologic Class:
Histamine H2
antagonists
Treatment and
prevention of
heartburn, acid
indigestion, and
sour stomach.
Treatment and
prevention of
heartburn, acid
indigestion, and sour
stomach.
CNS:
Confusion,
dizziness,
drowsiness,
hallucinations,
headache
CV:
Arrhythmias
GI:
Altered taste, black
tongue,
constipation, dark
stools, diarrhea,
drug-induced
hepatitis, nausea

Drug-drug:
-Glipzide- may
increase
hypoglycemic
effect
-warfarin- may
interfere with
warfarin
clearance.
Monitor patient
closely.
IVTT,
25mg,
q8
Assess patient for epigastric or
abdominal pain and frank or
occult blood in the stool, emesis,
or gastric aspirate.

Nurse should know that it may
cause false-positive results for
urine protein; test with
sulfosalicylic acid.

Inform patient that it may
cause drowsiness or dizziness.
Inform patient that increased
fluid and fiber intake may
minimize constipation.

Advise patient to report onset
of black, tarry stools; fever, sore
throat; diarrhea; dizziness; rash;
confusion; or hallucinations to
health car professional
promptly.

Inform patient that medication
may temporarily cause stools
and tongue to appear gray
black.

GENERIC NAME/
TRADE NAME

CLASSIFICATION

INDICATION

MECHANISM
OF ACTION

ADVERSE
REACTION

DRUG
INTERACTION

ROUTE/
FREQUENCY/
DOSAGE

NURSING INTERVERNTIONS
GENERIC
NAME:
PARACETAM
OL


BRAND
NAME:
(TEMPRA
FORTE)

Analgesics

( Non-opioid)
Antipyretics

Temporary relief
of pain and
discomfort from
headache, fever,
cold, flu, minor
muscular aches,
overexertion,
menstrual cramps,
toothache, minor
arthritic pain.

Paracetamol may
cause analgesia by
inhibiting CNS
prostaglandin
synthesis. The
mechanism of
morphine is
believed to involve
decreased
permeability of the
cell membrane to
sodium, which
results in
diminished
transmission of pain
impulses therefore
analgesia.
Hematologic:
hemolytic
anemia,
leukopenia,
neutropenia,
pancytopenia,
thrombocytopeni
a.
Hepatic:
liver damage,
jaundice
Metabolic:
hypoglycemia
Skin: rash,
urticuria


Barbiturates,
carbamapezine,
hydantoins,
isoniazid,
rifampin,
sulfinpyrazone:
May reduce
therapeutic
effect and
enhance
hepatotoxic
effects of
acetaminophen
with high doses
or long-term use
of these drugs.
Avoid use
together.

Lamotrigine:
Serum
lamotrigine
concentrations
may be reduced
and may
decrease
therapeutic
effects.

Warfarin: May
increase
250mg 7.5ml,
q 4,
PRN for Fever
Assess patients pain or
temperature before therapy
and regularly thereafter.

Asses patients drug history
and calculate total daily
dosage accordingly.

Be alert for signs of reactions
and drug interactions.

Assess patients and familys
knowledge of drug therapy.

Tell patient to keep track of
daily drug intake, including
OTC and prescription
medications.



hypoprothrombi
n-emic effect
with long-term
use of high
doses.Monitor
PT and INR
closely.


Zidovudine:
May increase
risk of bone
marrow
suppression
because of
impaired
zidovudine
metabolism.
Monitor patient
closely.



GENERIC NAME/
TRADE NAME

CLASSIFICATION

INDICATION

MECHANISM
OF ACTION

ADVERSE
REACTION

DRUG
INTERACTION

ROUTE/
FREQUENCY/
DOSAGE

NURSING INTERVERNTIONS
GENERIC
NAME:
Montelukast

BRAND
NAME:
Leukast
Therapeutic Class:
Anti asthmatic

Pharmacologic Class:
Leukotriene-
Receptor Antagonist
Asthma, seasonal
allergic rhinitis.
Perennial allergic
rhinitis
Reduces early and
late-phase
bronchoconstriction
from antigen
challenge
CNS: headache,
asthenia, dizziness,
fatigue, fever

EENT: dental pain,
nasal congestion

GI: abdominal
pain, dyspepsia,
infectious
gastroenteritis

GU: pyuria

Hematologic:
systemic
eosinophilia

Respiratory: cough

Skin: rash

Other: influenza,
trauma
Drug-drug:
phenobarbital,
rifampin: may
decrease
bioavailability of
montelukast
because of
hepatic
metabolism
induction.
Monitor patient
for effectiveness.

5mg 1chewable
Tablet OD HS
Inform patient to minimize GI
upset by eating small, frequent
servings of food and drinking of
plenty of fluids

Assess eosinophil count


Monitor temperature. Watch for
fever and symptoms of
infection.